John De Vos

VERY encouraging Phase 1 data for FT819: #iPSC-derived allogeneic #CARTcells show a promising safety profile and early signs of efficacy in lupus nephritis! Small cohorts and preliminary results, but an exciting step for off-the-shelf cell therapies. buff.ly/xmBLhdj

A first for CRISPR: powerful prime editing alters DNA directly in the human body #GeneTherapy buff.ly/de3OEU2

Similarly, Cellectis is shifting its focus from ex vivo allogeneic #CART cells therapies to in vivo CAR-T approaches. buff.ly/Go8L544

Caribou Biosciences’ shutdown highlights the challenges facing allogeneic CAR-T therapies. Indeed, emerging in vivo CAR-T approaches generate autologous CAR-T cells directly within the patient, potentially at a fraction of the cost of conventional ex vivo manufacturing. buff.ly/MpQ0vOX #CART

Progenitor resilience and the early onset of chronic lung diseases: #NHLBI workshop report @atscommunity.bsky.social academic.oup.com/ajrcmb/artic...

Recent safety events with Novartis and BMS highlight the challenge of translating #CART from life-threatening cancers to chronic autoimmune diseases. Meanwhile, Kyverna’s miv-cel continues to show encouraging efficacy and safety in stiff person syndrome. BLA planned by year-end. buff.ly/TIe8ymE

Century Therapeutics’ Allo-Evasion™ 5.0-edited CNTY-813 (#iPSC-derived islets) showed durable glycemic control in diabetic animal and clinical-scale manufacturing. IND submission planned for Q4 2026, with first clinical data expected in 2H 2027. buff.ly/EQ3CC3X

BlueRock Therapeutics’ #iPSC-derived cell therapy lemiretprocel (OpCT-001) has received orphan drug designation from both the FDA and EMA for inherited retinal diseases. Now in Phase 1/2a testing for retinitis pigmentosa, Usher syndrome & cone-rod dystrophies. #iPSC #CellTherapy buff.ly/JjjdBgP

China tests CAR-T therapies faster than the rest of the world but regulatory changes could slow them down. #CARTCells buff.ly/Dioelh7

Madam, I’m Adam 👇 #Palindromania

The most significant trend of the next decade is going to be that computers are getting smarter while people are getting dumber.

Fate’s #ACR2026 studies suggest #iPSC-derived #CARTs could become a compelling allogeneic platform: a potentially unlimited supply of a standardized, homogeneous product. Data cover FT819 in lupus - without conditioning/outpatient use - and CD19/CD38 FT839 in RA. buff.ly/1U7ulvd

Very nice review by @Joseph_C_Wu et al. on the use of #iPSCells in medicine, including manufacturing complexities. buff.ly/1rF5Czk

Early but promising results with armored #CARTcells targeting glypican-3 and co-expressing IL-15 and IL-21 in pediatric hepatoblastoma. Step by step, CAR-T cells are beginning to make solid tumors addressable. buff.ly/ZqJ8UbH

Craig Venter passed away. I'm old enough to remember the sequencing of the genome in 2001, by the team of Craig Venter (Celera Genomics), the Science cover, and an International public consortium, the Nature cover. buff.ly/InQ8izN

Gene therapy: A single dose of #CRISPR gene-editing therapy decreased cholesterol and triglycerides for at least a year. Comment in Nature : buff.ly/ehOREHV NEJM : buff.ly/j7xFm8P

Two extraordinary charts from today’s PISA test results: 1) School test scores continue to collapse internationally, underscoring how this is no longer a Covid effect but sustained decline. Those falls in reading and maths are equivalent to about two years of lost schooling.

In a Phase II trial for idiopathic pulmonary fibrosis, rentosertib reportedly lowered proteomic biological age in the treated group—potentially signalling disease regression, systemic rejuvenation, or both. If confirmed, this could be a landmark advance in gerobiology. buff.ly/WSFNu7T

Geoffrey Hinton admitted he was wrong that AI would replace radiologists. Healthcare demand is elastic, so cheaper/faster scan reading creates more scans, and radiologists do more than interpret images. What many people fail to consider is AI automating tasks is not the same as eliminating the job

Deaths in a Novartis #CARTCells clinical trial for autoimmune diseases: follow-up. www.fiercebiotech.com/biotech/nova...

⚠️ A reminder that #CARTcells expansion beyond cancer comes with real safety challenges. Novartis has paused 8 trials of its CAR-T therapy in autoimmune diseases after 3 patients died following severe immune reactions. A major setback for an otherwise highly promising field. buff.ly/ApFP5Iy

[Resources] #AlphaFold protein and PPI prediction databases 1️⃣ Predictomes (genome maintenance & H2A/H2b) predictomes.org 2️⃣ Flypredictome www.flyrnai.org/tools/fly_pr... 3️⃣ Human interactome prodata.swmed.edu/humanPPI 4️⃣ BFVD (viral proteins) bfvd.steineggerlab.workers.dev 1/2

🧬 Connecting new ideas in Stem Cell Biology! Join leading scientists from Europe, Canada & the U.S. for the 6th International Conference on developmental, adult and cancer Stem Cells. 📍 Lyon, France 📅 October 1–2, 2026 By Aurastem buff.ly/NRKL0Pg #StemCells, #Development and #Cancer

@biorxivpreprint.bsky.social A Cytokine Receptor Signaling Atlas Reveals How STAT Mosaics Fine-Tune T Cell Function www.biorxiv.org/content/10.6... @stanforduniversity.bsky.social

🔥📣[COMMUNIQUE] de l'ancien Président de la Conférence des Présidents d'Universités @jlsalzmann.bsky.social, lui-même Professeur de médecine sur les 850 études de l'IHU suspectées illégales. Sans précédent sans l'Histoire mondiale. Il n'a pas de mots assez durs. Et la justice ne fait... rien. RT SVP🔽

His words came true. Democracy can hardly be expected to flourish in societies where political and economic power is being progressively concentrated and centralized. But the progress of technology has led and is still leading to just such a concentration and centralization of power. Aldous Huxley

Anti-CD19 #CARTCells can persist up to 10 years after infusion in patients with lymphoid malignancies. In one patient CART cells comprised 1.2% of circulating T cells at 9y. Long-term persisting CART cells were predominant double-negative (CD4−CD8−), effector-memory-like phenotype. buff.ly/FBYeuwR

Prenez soin de vos yeux ce soir!

A growing number of private firms are offering researchers artificial-intelligence tools for scrutinizing manuscripts before publication go.nature.com/4wSqQgQ

Encouraging results for CAR-T in recurrent glioblastoma: intracranial B7-H3 CAR-T (TX103) was well tolerated in a Phase 1 trial (n=15), with no DLTs. Median OS reached 19.1 months, with 66.7% alive at 12 months and one sustained complete response. Phase 2 warranted. #CARTcells buff.ly/1hWb3c9

‘A chilling effect’: China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts . buff.ly/VydvQje/

Against all odds, with an HHS that has defunded mRNA research programs, the FDA just approved the first mRNA flu vaccine

Thrilled to post thread re: new single-cell lineage of mouse embryo reconstructed w/ DNA Typewriter. One animal, zygote to late organogenesis (E13.5). Tree has 1,340,794 transcriptionally profiled, annotated tips (cells), 1,142,588 dated internal nodes, rooted at zygote 1/n

Global warming is already harming human health in countless ways. We can now add smoke-related deaths to the growing list. By David Wallace-Wells of the NYT. www.nytimes.com/2026/07/22/o...

Hopstem has received FDA IND clearance and Fast Track designation for its allogeneic #iPSCells-derived forebrain neural progenitors therapy in both hemorrhagic stroke and traumatic brain injury. Hopstem is a Chinese company (Hangzhou) also based in Houston. #StemCell #Stroke

“You will get the country you voted for. That country is one where we will no longer innovate. We will be less secure, less healthy, and less wealthy because some community of people who influence what this country is do not see the value of science” - Neil deGrasse Tyson — It’s already too late.

📣 SAVE THE DATE! The 8th FSSCR Meeting will be held in Paris from Tuesday 11 to Thursday 13 May 2027. As usual, our scientific committee is curating an exceptional lineup of prestigious speakers (to be announced soon) from some of the most renowned research centres. STAY TUNED. #FSSCR #StemCells

@kenaitx.bsky.social has completed enrollment in the Phase 1b/2a REPLACE™ trial of RNDP-001, an off-the-shelf allogeneic dopaminergic neuron replacement therapy derived from #iPSCells. Early efficacy data are now eagerly awaited. #CellTherapy buff.ly/XD3llbo

Awesome #evolution tool shows when humans separated from other species: 1bn years fungi, 6m years chimpanzees. Source: buff.ly/2l0gV64

Tech companies treating cautionary tales from science fiction as product roadmaps is one of my least favorite things about this timeline.

An AI-generated small-molecule inhibitor treats fibrosis in vivo and in phase I clinical trials go.nature.com/3IvPOuI rdcu.be/d8EOQ

In June, genome-editing pioneer Sangamo Therapeutics filed for bankruptcy. A change of era for one of the field's early trailblazers. buff.ly/wgGhrdh

From cloning to gene-editing: the enduring legacy of Dolly the sheep. 30 years after. buff.ly/5REIgRz

📢 Les inscriptions au Diplôme Universitaire « Thérapies Cellulaire & Génique – Médecine Régénératrice » de la Faculté de Médecine de Montpellier sont ouvertes! 📅 Formation intensive du 9 au 20 novembre 2026 💻 Accessible en présentiel ou en distanciel 😀 Inscriptions : buff.ly/5jebkp6

Cette animation est saisissante. Elle montre, en seulement quelques secondes, l'accélération spectaculaire de la fréquence des vagues de chaleur au cours des 126 dernières années en France. 1/3

The pace of AI progress is exponential. So is its capacity to create value. This argues against an AI bubble.